🇬🇷
Peptide Laws in Greece
GR · Europe · 23 peptides tracked
Grey AreaEnforcement: Lenient
Are Peptides Legal in Greece?
Greece follows the EU framework through EOF/NOM, but practical enforcement is lower than in northern Europe. The regulatory focus tends to be on larger-scale commercial operations rather than individual buyers. Research peptides from EU-based vendors are relatively accessible. Semaglutide is available by prescription, though it may be easier to access certain peptides through pharmacies with a doctor's note than in stricter EU countries.
4
Legal16
Grey Area3
PrescriptionCan You Buy Peptides in Greece?
4 peptide(s) are legal to buy in Greece, including GHK-Cu, NAD+, Glutathione, Vitamin B12. 3 peptide(s) require a valid prescription, including Tirzepatide, Semaglutide, CJC-1295. 16 peptide(s) fall into a legal grey area: Selank, MOTS-c, TB-500, Ipamorelin, Semax, and 11 more. These may be available for research purposes but their legality for personal use is ambiguous.
Traveling to Greece with Peptides
When traveling to Greece with peptides, the legality depends on each peptide's classification. Prescription peptides (Tirzepatide, Semaglutide, CJC-1295) typically require documentation such as a prescription or doctor's letter when crossing borders. Enforcement in Greece is rated as "Lenient." Always declare pharmaceutical products at customs and carry documentation of any prescriptions.
New to peptides? Start with the basics on peptide.camp →
Need to source peptides for Greece? Get verified wholesale quotes on peptide.broker →
Traveling to Greece with peptides? TSA tips, packing guides & the peptide travel case on peptide.travel →
Peptide Regulations in Greece
| Peptide | Status | Rx Required | Schedule | Detail | Source |
|---|---|---|---|---|---|
| Tirzepatide | Prescription | Yes | EMA Authorized (Rx) | EMA-authorized. Mounjaro. Prescription required. As an EU member state, Article 6(1) of Directive 2001/83/EC applies: no medicinal product may be placed on the market of a Member State unless a marketing authorisation has been issued by the competent authorities of that Member State or under the centralised procedure. No EU or national marketing authorisation for this substance was identified, so it is an unauthorised medicinal product. National regulator: SUKL (Czechia) / EOF (Greece). Country-specific offence provisions and penalties have NOT been verified for this jurisdiction. | Official |
| Selank | Grey Area | No | Not Scheduled / Unauthorized | No EMA authorization. Approved in Russia. Research-label available. Not on WADA prohibited list. As an EU member state, Article 6(1) of Directive 2001/83/EC applies: no medicinal product may be placed on the market of a Member State unless a marketing authorisation has been issued by the competent authorities of that Member State or under the centralised procedure. No EU or national marketing authorisation for this substance was identified, so it is an unauthorised medicinal product. National regulator: SUKL (Czechia) / EOF (Greece). Country-specific offence provisions and penalties have NOT been verified for this jurisdiction. | Official |
| MOTS-c | Grey Area | No | Not Scheduled / Unauthorized | Research peptide. No EMA authorization. WADA banned. Minimal enforcement attention. As an EU member state, Article 6(1) of Directive 2001/83/EC applies: no medicinal product may be placed on the market of a Member State unless a marketing authorisation has been issued by the competent authorities of that Member State or under the centralised procedure. No EU or national marketing authorisation for this substance was identified, so it is an unauthorised medicinal product. National regulator: SUKL (Czechia) / EOF (Greece). Country-specific offence provisions and penalties have NOT been verified for this jurisdiction. | Official |
| TB-500 | Grey Area | No | Not Scheduled / Unauthorized | No EMA authorization. Same framework as BPC-157. Research-label purchase tolerated. WADA banned. As an EU member state, Article 6(1) of Directive 2001/83/EC applies: no medicinal product may be placed on the market of a Member State unless a marketing authorisation has been issued by the competent authorities of that Member State or under the centralised procedure. No EU or national marketing authorisation for this substance was identified, so it is an unauthorised medicinal product. National regulator: SUKL (Czechia) / EOF (Greece). Country-specific offence provisions and penalties have NOT been verified for this jurisdiction. | Official |
| GHK-Cu | Legal | No | Cosmetic Ingredient | Legal cosmetic ingredient under EU Cosmetics Regulation 1223/2009. Topical forms sold freely. Injectable form unauthorized. As an EU member state, Article 6(1) of Directive 2001/83/EC applies: no medicinal product may be placed on the market of a Member State unless a marketing authorisation has been issued by the competent authorities of that Member State or under the centralised procedure. No EU or national marketing authorisation for this substance was identified, so it is an unauthorised medicinal product. National regulator: SUKL (Czechia) / EOF (Greece). Country-specific offence provisions and penalties have NOT been verified for this jurisdiction. | Official |
| Ipamorelin | Grey Area | No | Not Scheduled / Unauthorized | No EMA authorization. GHRP. WADA banned. Research-label available. As an EU member state, Article 6(1) of Directive 2001/83/EC applies: no medicinal product may be placed on the market of a Member State unless a marketing authorisation has been issued by the competent authorities of that Member State or under the centralised procedure. No EU or national marketing authorisation for this substance was identified, so it is an unauthorised medicinal product. National regulator: SUKL (Czechia) / EOF (Greece). Country-specific offence provisions and penalties have NOT been verified for this jurisdiction. | Official |
| Semaglutide | Prescription | Yes | EMA Authorized (Rx) | EMA-authorized. Ozempic/Wegovy. Prescription required. Massive counterfeit/compounded market. EMA warned of 'sharp rise in illegal medicines'. As an EU member state, Article 6(1) of Directive 2001/83/EC applies: no medicinal product may be placed on the market of a Member State unless a marketing authorisation has been issued by the competent authorities of that Member State or under the centralised procedure. No EU or national marketing authorisation for this substance was identified, so it is an unauthorised medicinal product. National regulator: SUKL (Czechia) / EOF (Greece). Country-specific offence provisions and penalties have NOT been verified for this jurisdiction. | Official |
| CJC-1295 | Prescription | Yes | Unauthorized Medicine | No EMA authorization. GHRH analog. WADA banned. Research-label available. As an EU member state, Article 6(1) of Directive 2001/83/EC applies: no medicinal product may be placed on the market of a Member State unless a marketing authorisation has been issued by the competent authorities of that Member State or under the centralised procedure. No EU or national marketing authorisation for this substance was identified, so it is an unauthorised medicinal product. National regulator: SUKL (Czechia) / EOF (Greece). Country-specific offence provisions and penalties have NOT been verified for this jurisdiction. | Official |
| Semax | Grey Area | No | Not Scheduled / Unauthorized | No EMA authorization. Approved in Russia. Research-label available. Not on WADA prohibited list. As an EU member state, Article 6(1) of Directive 2001/83/EC applies: no medicinal product may be placed on the market of a Member State unless a marketing authorisation has been issued by the competent authorities of that Member State or under the centralised procedure. No EU or national marketing authorisation for this substance was identified, so it is an unauthorised medicinal product. National regulator: SUKL (Czechia) / EOF (Greece). Country-specific offence provisions and penalties have NOT been verified for this jurisdiction. | Official |
| BPC-157 | Grey Area | No | Not Scheduled / Unauthorized | No EMA authorization. Unauthorized medicine under EU Directive 2001/83/EC. Research-label purchase tolerated in most countries. WADA banned (S0). As an EU member state, Article 6(1) of Directive 2001/83/EC applies: no medicinal product may be placed on the market of a Member State unless a marketing authorisation has been issued by the competent authorities of that Member State or under the centralised procedure. No EU or national marketing authorisation for this substance was identified, so it is an unauthorised medicinal product. National regulator: SUKL (Czechia) / EOF (Greece). Country-specific offence provisions and penalties have NOT been verified for this jurisdiction. | Official |
| NAD+ | Legal | No | Supplement / Novel Food | Supplements (NMN/NR) widely sold. IV infusions at clinics. NMN awaiting EFSA novel food assessment (Uthever 2025). As an EU member state, Article 6(1) of Directive 2001/83/EC applies: no medicinal product may be placed on the market of a Member State unless a marketing authorisation has been issued by the competent authorities of that Member State or under the centralised procedure. No EU or national marketing authorisation for this substance was identified, so it is an unauthorised medicinal product. National regulator: SUKL (Czechia) / EOF (Greece). Country-specific offence provisions and penalties have NOT been verified for this jurisdiction. | Official |
| Retatrutide | Grey Area | No | Investigational | Phase 3 clinical trials. No EMA approval. Any online sales illegal. FDA warned against compounded versions. As an EU member state, Article 6(1) of Directive 2001/83/EC applies: no medicinal product may be placed on the market of a Member State unless a marketing authorisation has been issued by the competent authorities of that Member State or under the centralised procedure. No EU or national marketing authorisation for this substance was identified, so it is an unauthorised medicinal product. National regulator: SUKL (Czechia) / EOF (Greece). Country-specific offence provisions and penalties have NOT been verified for this jurisdiction. | Official |
| AOD-9604 | Grey Area | No | Not Scheduled / Unauthorized | No EMA authorization. GH fragment. Research-label available. As an EU member state, Article 6(1) of Directive 2001/83/EC applies: no medicinal product may be placed on the market of a Member State unless a marketing authorisation has been issued by the competent authorities of that Member State or under the centralised procedure. No EU or national marketing authorisation for this substance was identified, so it is an unauthorised medicinal product. National regulator: SUKL (Czechia) / EOF (Greece). Country-specific offence provisions and penalties have NOT been verified for this jurisdiction. | Official |
| Glutathione | Legal | No | Supplement | — | Unsourced |
| DSIP | Grey Area | No | Not Scheduled / Unauthorized | — | Unsourced |
| Epithalon | Grey Area | No | Not Scheduled / Unauthorized | — | Unsourced |
| KPV | Grey Area | No | Not Scheduled / Unauthorized | — | Unsourced |
| HGH | Grey Area | No | Unregistered | — | Unsourced |
| Liraglutide | Grey Area | No | Unregistered | — | Unsourced |
| Melanotan II | Grey Area | No | Not Scheduled / Unauthorized | — | Unsourced |
| Vitamin B12 | Legal | No | Supplement | — | Unsourced |
| PT-141 | Grey Area | No | Unregistered | — | Unsourced |
| MK-677 | Grey Area | No | Unregistered | — | Unsourced |
About the sources on this page
Entries marked Official cite a government regulator, legislation or an official gazette. Some entries currently carry no source at all.
We show these entries rather than hiding them, but they should not be relied on. Nothing on this site is legal advice. Verify against the national regulator before acting, and if you can point us at a better source please submit an update.
Data is researcher-verified but not legal advice. Always consult local regulations before purchasing, importing, or traveling with peptides. Last verified: 2026-02-28.